Untreated
PEG-LPrA2 treated
Lean-C
Lean-I
Lean-II
DIO-C
DIO-I
DIO-II
Mammary tumors
0/6 (0%)
0/7 (0%)
3/14 (21%)
Lymphoid tumors
1/7 (14%)
2/7 (29%)
4/7 (57%)
Skin tumors
4/6 (67%)
8/14 (57%)
3/7 (43%)
5/7 (71%)